FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

New Lilly Drug Meets Endpoints on Weight Loss

[ Price : $8.95]

Eli Lilly says new Phase 2 data on weight-loss candidate retatrutide met primary and secondary endpoints.

Info Collection on e-Import Entries Revised

[ Price : $8.95]

Federal Register notice: FDA sends to OMB an information collection revision entitled Imports and Electronic Import Entries.

FDA Withdraws Oxandrolone NDA/ANDAs

[ Price : $8.95]

Federal Register notice: FDA withdraws the approval of a Gemini Laboratories NDA for Oxandrin (oxandrolone) tablets and four ANDAs...

Supply Chain Violations at Safe Chain Solutions

[ Price : $8.95]

FDA warns Cambridge, MD-based Safe Chain Solutions about violations of the Drug Supply Chain Security Act in its work as a wholesa...

DTC Efficacy and Risk Information Guidance

[ Price : $8.95]

FDA publishes a guidance on how to present more consumer-friendly efficacy and risk information in direct-to-consumer promotional ...

QCARD Can Improve Oncology Submissions

[ Price : $8.95]

Two Oncology Center of Excellence executives describe the benefits of the new QCARD initiative intended to improve study proposals...

Schumer Pushes Drug Shortage Legislation

[ Price : $8.95]

Senate majority leader Chuck Schumer says FDA must develop a plan to deal with drug shortages and Congress must pursue a legislati...

Wholesaling Prohibition Guidance

[ Price : $8.95]

FDA publishes a draft guidance about the prohibition on wholesaling of compounded drugs under Section 503B of the Federal Food, Dr...

Complete Response on Higher Dose Eylea

[ Price : $8.95]

FDA issues a complete response letter on a Regeneron Pharmaceuticals BLA for Eylea (aflibercept 8 mg), a higher dose of the eye dr...

UCBs Rystiggo Approved for Myasthenia Gravis

[ Price : $8.95]

FDA approves a UCB BLA for Rystiggo (rozanolixizumab-noli) for treating generalized myasthenia gravis in certain adult patients.